JP2023507497A - ワクチンアジュバントとしてのポリマーナノ粒子 - Google Patents

ワクチンアジュバントとしてのポリマーナノ粒子 Download PDF

Info

Publication number
JP2023507497A
JP2023507497A JP2022538064A JP2022538064A JP2023507497A JP 2023507497 A JP2023507497 A JP 2023507497A JP 2022538064 A JP2022538064 A JP 2022538064A JP 2022538064 A JP2022538064 A JP 2022538064A JP 2023507497 A JP2023507497 A JP 2023507497A
Authority
JP
Japan
Prior art keywords
nanoparticles
composition
particles
response
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538064A
Other languages
English (en)
Japanese (ja)
Inventor
ラヴェル エド
ムニョス－ウォルフ ナターリア
Original Assignee
ザ プロボスト フェローズ スカラーズ アンド アザー メンバーズ オブ ボード オブ トリニティ カレッジ ダブリン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ プロボスト フェローズ スカラーズ アンド アザー メンバーズ オブ ボード オブ トリニティ カレッジ ダブリン filed Critical ザ プロボスト フェローズ スカラーズ アンド アザー メンバーズ オブ ボード オブ トリニティ カレッジ ダブリン
Publication of JP2023507497A publication Critical patent/JP2023507497A/ja
Priority to JP2025189065A priority Critical patent/JP2026015426A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2022538064A 2019-12-20 2020-12-21 ワクチンアジュバントとしてのポリマーナノ粒子 Pending JP2023507497A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025189065A JP2026015426A (ja) 2019-12-20 2025-11-10 ワクチンアジュバントとしてのポリマーナノ粒子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1918963.8A GB201918963D0 (en) 2019-12-20 2019-12-20 Polymeric nanoparticles as vaccine adjuvants
GB1918963.8 2019-12-20
PCT/EP2020/087456 WO2021123430A1 (en) 2019-12-20 2020-12-21 Polymeric nanoparticles as vaccine adjuvants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025189065A Division JP2026015426A (ja) 2019-12-20 2025-11-10 ワクチンアジュバントとしてのポリマーナノ粒子

Publications (1)

Publication Number Publication Date
JP2023507497A true JP2023507497A (ja) 2023-02-22

Family

ID=69322661

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022538064A Pending JP2023507497A (ja) 2019-12-20 2020-12-21 ワクチンアジュバントとしてのポリマーナノ粒子
JP2025189065A Pending JP2026015426A (ja) 2019-12-20 2025-11-10 ワクチンアジュバントとしてのポリマーナノ粒子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025189065A Pending JP2026015426A (ja) 2019-12-20 2025-11-10 ワクチンアジュバントとしてのポリマーナノ粒子

Country Status (8)

Country Link
US (1) US20230218752A1 (https=)
EP (1) EP4076519A1 (https=)
JP (2) JP2023507497A (https=)
CN (1) CN115279401A (https=)
AU (1) AU2020407306A1 (https=)
CA (1) CA3162350A1 (https=)
GB (1) GB201918963D0 (https=)
WO (1) WO2021123430A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114657210B (zh) * 2022-03-03 2023-08-11 中山大学孙逸仙纪念医院 一种基于负载gsdmd蛋白n端肽段的纳米材料及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501341A (ja) * 2008-08-29 2012-01-19 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル） 免疫療法用ナノ粒子

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
JP4526708B2 (ja) 1998-09-01 2010-08-18 メリオン リサーチ スリー リミテッド 細胞を媒介した免疫応答を誘導する方法及びそのための非経口ワクチン製剤
US8021689B2 (en) * 2006-02-21 2011-09-20 Ecole Polytechnique Federale de Lausanne (“EPFL”) Nanoparticles for immunotherapy
JP6008345B2 (ja) 2009-02-27 2016-10-19 東レ株式会社 免疫原性組成物
US9572894B2 (en) 2010-10-18 2017-02-21 The University Of Iowa Research Foundation Biodegradable particulate formulations
CN104338126B (zh) * 2013-08-08 2018-05-04 中国科学院过程工程研究所 一种具有治疗或预防hpv病毒的疫苗组合物及其应用
US10117886B2 (en) 2014-05-30 2018-11-06 Hao Cheng Hyaluronidase and a low density second PEG layer on the surface of therapeutic-encapsulated nanoparticles to enhance nanoparticle diffusion and circulation
MX2018010586A (es) * 2016-03-02 2019-03-28 Univ Texas Nanovacuna de activacion de "sting" para inmunoterapia.
US11925693B2 (en) * 2017-07-27 2024-03-12 The Board Of Trustees Of The Leland Stanford Junior University Polymeric nanoparticles for enhanced cancer immunotherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501341A (ja) * 2008-08-29 2012-01-19 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル） 免疫療法用ナノ粒子

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Synthetic Polymeric Mixed Micelles Targeting Lymph Nodes Trigger Enhanced Cellular and Humoral Immun", ACS APPLIED MATERIALS & INTERFACES, vol. 10, no. 3, JPN6024048064, 2018, pages 2874 - 2889, ISSN: 0005636566 *

Also Published As

Publication number Publication date
JP2026015426A (ja) 2026-01-29
CA3162350A1 (en) 2021-06-24
EP4076519A1 (en) 2022-10-26
GB201918963D0 (en) 2020-02-05
AU2020407306A1 (en) 2022-07-07
US20230218752A1 (en) 2023-07-13
WO2021123430A1 (en) 2021-06-24
CN115279401A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
Zhao et al. Vaccine adjuvants: mechanisms and platforms
Feng et al. Immunomodulatory nanosystems
Foged Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems
Demento et al. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype
Sun et al. The quest for nanoparticle-powered vaccines in cancer immunotherapy
CN102056622B (zh) 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
Tan et al. Understanding structure–function relationships of nanoadjuvants for enhanced cancer vaccine efficacy
van Riet et al. Combatting infectious diseases; nanotechnology as a platform for rational vaccine design
JP2026015426A (ja) ワクチンアジュバントとしてのポリマーナノ粒子
Zeng et al. In-depth review of delivery carriers associated with vaccine adjuvants: current status and future perspectives
Khalifa et al. Subunit antigen delivery: emulsion and liposomal adjuvants for next-generation vaccines
Espuelas Delivery systems for the treatment and prevention of leishmaniasis
Rane et al. Polymer-Based Vaccines
Ohta Cholesteryl Pullulan Nanoparticles-Encapsulated TNF-a: An Effective Mucosal Vaccine Adjuvant Against
Noureddine et al. Nanoparticle Vaccines for Immunotherapy: From Design to Clinical Trials
Jyoti et al. played by nanoimmunoadjuvants
AU2016425290A1 (en) Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects
Lu EVALUATION OF ALPHA-D-GLUCAN NANOPARTICLE AS A VACCINE ADJUVANT
Matsuo et al. Application of Poly (γ‐Glutamic Acid)‐Based Nanoparticles as Antigen Delivery Carriers in Cancer Immunotherapy
Monteiro Garrido Castro e Silva PLGA-based particulate vaccine delivery systems for immunotherapy of cancer
Nayak et al. Self-Adjuvanted Nanovaccines: Concept and Applications
Yanasarn Lipid Based Nanocarriers for Chemotherapeutic Drug Docetaxel and Vaccine Delivery
Koppolu Development and Evaluation of Chitosan Particle Based Antigen Delivery Systems for Enhanced Antigen Specific Immune Response
HK1155642B (en) Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250424

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250708